A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

NCT05426369 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Thrombocytopenia (CIT)

Interventions

BIOLOGICAL: Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein

Sponsor

Sichuan Clover Biopharmaceuticals, Inc.